



IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant(s):

Lars HOLMGREN et al.

Application No.:

09/332,063

Group:

1642

Filed:

June 14, 1999

Examiner:

A. Harris

For:

ANGIOGENESIS RELATED MOLECULES

Date: OCT 13 1999

Docket No.: 3362-101P

LARGE ENTITY TRANSMITTAL FORM

Assistant Commissioner for Patents Washington, DC 20231

RECEIVED
OCT 1 4 1999

TECH CENTER 1600/2900

Sir:

Transmitted herewith is an amendment in the above-identified application.

The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.

The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	32	-	32	=	0	\$ 22	\$0
INDEPENDENT	2	-	3		0	\$ 82	\$0
FIRST PRESENTATION OF A MULTIPLE CLAIM						\$270	\$0
						TOTAL	\$0

	Petition for month(s) extension of time pursuant to 37 CFR §§ 1.17 and 1.136(a) for the extension of time.	\$
<u>X</u>	No fee is required.	
_	A check in the amount of \$ is enclosed.	
_	Please charge Deposit Account No. 02-2448 in the amount of \$ This form is submitted in triplicate.	

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Maryune Tio Ha Gerald M. Murphy Jr. Reg. No. 28,977 Mary Anne Liotta, Ph.D.

Reg. No. 40,069

P. O. Box 747 Falls Church, VA 22040-0747 (703) 205-8000

GMM/MAL/LPS 3362-101P



HOB TO

SEQUENCE PATENT 3362-101P

IN THE U.S. PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Lars HOLMGREN et al.

RECEIVED

APPLICATION NO.:

09/332,063

GROUP: 1642

OCT 1 4 1999

FILED:

June 14, 1999

EXAMINER: A. Harris

SQL 1 1 1777.

FOR:

ANGIOGENESIS RELATED MOLECULES

TECH CENTER 1600/290**

AMENDMENT

Honorable Commissioner of Patents Washington, D.C. 20231

OCT 13 1999

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed September 17, 1999, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

IN THE SPECIFICATION

Please amend the specification as follows:

Please delete the original Sequence Listing, filed on June 14, 1999. Please insert the Substitute Sequence Listing enclosed herewith immediately after the abstract.

REMARKS

Enclosed herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a Substitute Sequence Listing to be inserted into the specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the specification.